A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs
Who is this study for? Adult patients with atrial fibrillation
What treatments are being studied? Flecainide+Sotalol
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• ≥ 18 years of age
• History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
• ECG that was recorded within 1 month of randomization showing AF
• Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
• Able to give informed consent
Locations
United States
Illinois
Jesse Brown VA Medical Center
NOT_YET_RECRUITING
Chicago
Rush University Medical Center
NOT_YET_RECRUITING
Chicago
University of Illinois at Chicago
RECRUITING
Chicago
Advocate Christ Medical Center
NOT_YET_RECRUITING
Oak Lawn
Contact Information
Primary
Dawood Darbar, M.D.
darbar@uic.edu
6158879032
Time Frame
Start Date: 2020-12-31
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 162
Treatments
Experimental: flecainide 1st
flecainide x 6 months, then crossover to sotalol x 6 months
Experimental: sotalol 1st
sotalol x 6 months, then crossover to flecainide x 6 months
Related Therapeutic Areas
Sponsors
Leads: University of Illinois at Chicago
Collaborators: Medtronic